Acute ischemic stroke is the second leading cause of mortality and a key cause of long-term disability worldwide1. Philips is a technology leader committed to strengthening stroke care, helping to build a system that better serves patients across their entire care experience. This includes not only developing the right solutions but also driving advocacy for better access to stroke care globally. Together, we can expand access and create a better care pathway that speeds up diagnostic decisions, improving stroke care and patient outcomes to make a difference for stroke patients worldwide.
See how Philips can help you save critical time to help improve stroke patient outcomes, from emergency care to fast diagnosis and confident treatment to post-stroke patient care.
Save time by creating neurology scans that visualize vitally important characteristics. Decide based on images with enhanced grey/white matter differentiation and reduction in beam-hardening artifacts. Philips Spectral CT 7500 increases diagnostic confidence due to improved lesion conspicuity.9
Interact with StrokeViewer from Azurion at tableside without breaking sterility to streamline stroke workflows. Use of StrokeViewer reduces initially undetected LVOs by 20%5, which potentially increases the number of patients treated with endovascular thrombectomy (EVT).
We are investigating if more eligible acute stroke patients can be treated by bringing them directly to the angio suite for diagnosis and treatment. A single-center study showed door-to-groin time reduced from 70 to 16 minutes (conventional workflow vs DTAS), with better 90-day outcomes10.
Since implementing Philips’ patient monitoring technology in 2015, Saratoga Hospital has reduced patient transfers to the intensive care unit (ICU) by 63 percent and eliminated patient codes within its 20-bed orthopedic unit, which dropped from three or four codes per year to zero.
“I think it’s imperative that we set up stroke systems in such a way that everyone on the planet has access to them.“
Dr. Mayank Goyal Clinical Professor, University of Calgary, Alberta, Canada
“Stroke typically ranks among the first two major causes of death and remains the number one cause of long-term disability among adults worldwide. So it’s a huge healthcare problem.“
Dr. Raul G. Nogueira Director of UPMC Stroke Institute, Professor of Neurology, UPMC, Pittsburgh, PA, USA
“The time is now for a coordinated approach to revolutionize stroke care, bringing together investment in care and treatment, infrastructure, awareness and a focus on effective policymaking.”
Dr. Carla Goulart Peron Chief Medical Officer, Royal Philips, Amsterdam
A health economic analysis published in 2023 in the Journal of NeuroInterventional Surgery (JNIS) shows an innovative approach to the stroke care pathway reduced costs by an average of EUR 2,848 (~USD 3,120) per patient. The retrospective analysis looked at data from the controlled single-center ANGIOCAT clinical trial conducted at the Vall d’Hebron University Hospital Stroke Unit (Barcelona, Spain)11. Earlier results from this study demonstrated that a ‘Direct-to-Angio Suite’ (DTAS) pathway improves clinical outcomes for patients who have suffered a stroke.
The World Stroke Organization (WSO) is calling for action with its global policy agenda, which features advocacy of stroke prevention, stroke recognition, quality stroke services, stroke rehabilitation and recovery for life after stroke, and action and accountability by governments. The joint WSO-Philips policy paper proposes six policy interventions to improve outcomes, and reduce direct costs with substantial potential savings, releasing essential resources for other priorities across struggling healthcare systems.
[1] www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
[2] Saini V, et al. Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology. 2021;97:S6-S16
[3] StrokeViewer is a trademark of Nicolab.
[4]The results achieved in this first Azurion lab performance study (2017) have been verified by an independent third party. Results are specific to the institution where they were obtained (St. Antonius hospital, Nieuwegein, The Netherlands) and may not reflect the results achievable at other institutions.
[5] Fasen, et al. Neuroradiology. 2022.
[6]Multicenter Innovate study across a leading Hub and Spoke network in The Netherlands in 2020, data collection ongoing. Streamlined stroke workflow | StrokeViewer | Nicolab
[7] Lindsay P, et al. World Stroke Organization global stroke services guidelines and action plan. Int J Stroke. 2014 Oct;9 Suppl A100:4-13
[8] Saver JL, et al. The “golden hour” and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010 Jul;41(7):1431-9.
[9] Analysis by SNUH - Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[10] www.ahajournals.org/doi/10.1161/STROKEAHA.118.021989
[11] Requena M, Vanden Bavière H, Verma S, et al. Cost-utility of direct transfer to angiography suite (DTAS) bypassing conventional imaging for patients with acute ischemic stroke in Spain: results from the ANGIOCAT trial. Journal of NeuroInterventional Surgery Published Online First: 27 April 2023. doi: 10.1136/jnis-2023-020275
*This solution is not available in all countries. Consult your local Philips representative for more detailed information.
**Philips ePatch® is a Class IIa medical device and validated as an Ambulatory ECG device (Holter) using the Harmonized Standard ISO60601-2-47 and developed using EN13485 as a quality management system.
You are about to visit a Philips global content page
ContinueThe information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).
By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.